Our own Alvin Chin, Prostate Cancer Survivor & Advocate, Virginia Prostate Coalition, joins oncologists Howard Scher MD, Donald S. Coffey, PhD, Peter S. Nelson, MD and representatives from
research and the Pharma industry for a round table discussion April 23.
You can make your voice heard by joining the conference by phone and emailing questions during the Q&A period.
Hosted by the Prostate Cancer Foundation, this roundtable discussion will feature commentary from eight U.S. experts in the field of prostate cancer research and treatment. The program will focus on the following areas:
* The current prevalence of prostate cancer
* Reaching beyond the PSA screening debate
* Promising scientific breakthroughs
* Challenges ahead for research and discovery
* Funding for continued research
* Models for furthering progress
WHERE:
The National Press Club – First Amendment Lounge
529 14th Street NW, Washington D.C. and via telephone access.
Call-in number: 800/550.7798 (U.S. & Canada) 213/233.3044 (International) Conference ID: 3154713
WHEN: Thursday, April 23
11:00 am – Registration
11:15 am – Program begins and phone line opens
12:30 pm – Program concludes
To ask questions by email contact dzenka@pcf.org.
WHO:
Josh Wolfe, Moderator
Co-founder, Managing Partner of Lux Capital
Editor of the Forbes Wolfe Emerging Tech Report
Alvin Chin, Prostate Cancer Survivor & Advocate, Virginia Prostate Coalition
Donald S. Coffey, PhD, Professor of Urology, Oncology, and Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine
Captain Melissa Kaime, MD, Director, Department of Defense, CDMRP
Peter S. Nelson, MD,
Professor of Medicine and Oncology
Fred Hutchinson Cancer Research Center and the University of Washington
Howard Scher, MD, Chief of the Genitourinary Oncology
Memorial Sloan-Kettering Cancer Center
Padmanee Sharma, MD, PhD, Researcher
University of Texas M. D. Anderson Cancer Research Center
Jonathan W. Simons, MD
President, CEO and David Koch Chair, Prostate Cancer Foundation
David E. Wheadon, MD
Senior Vice President of Scientific & Regulatory Affairs, PhRMA
Joel T Nowak MA, MSW
Leave A Comment